Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types.
In a
separate, concurrent agreement, Radiopharm acquired from NanoMab the imaging
rights of NM-01 for the strategic Chinese market and worldwide IP rights for
any therapeutic use (previously a licencing right).
Radiopharm
will shortly initiate a Phase 1 therapeutic trial in Australia in patients with
PD-L1 + non - small cell lung cancer (NSCLC).
Lantheus
provides innovative diagnostics, targeted therapeutics and artificial
intelligence (AI) solutions that empower clinicians to Find, Fight and Follow
disease. Lantheus holds the exclusive imaging rights to NM-01, apart from
China, and recently commenced a Phase 2 clinical trial of NM-01 to evaluate
PD-L1 expression in NSCLC patients.
Pursuant
to the collaboration agreement, Lantheus will provide the diagnostic product
candidate of NM-01 to Radiopharm for use in its therapeutic clinical trials.
To
read more please visit:
Source:
RAD